/IONS
IONS Stock - Ionis Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$79.57+2.50%
+$1.94 (+2.50%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.91
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).68
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+9.1%upside
Target: $86.81
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IONS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$78.77 – $80.37
TARGET (TP)$86.85
STOP LOSS$73.20
RISK/REWARD1:1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.30
52W High$83.61
52W Low$23.95
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $705.14M | $787.65M | $587.37M | $810.46M | $729.26M |
| Gross Profit | $693.92M | $778.51M | $573.25M | $799.61M | $717.32M |
| Gross Margin | 98.4% | 98.8% | 97.6% | 98.7% | 98.4% |
| Operating Income | $-475,081,000 | $-353,730,000 | $-410,191,000 | $-30,186,000 | $-172,082,000 |
| Net Income | $-453,897,000 | $-366,286,000 | $-269,722,000 | $-28,597,000 | $-444,263,000 |
| Net Margin | -64.4% | -46.5% | -45.9% | -3.5% | -60.9% |
| EPS | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.18 |
Company Overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Visit WebsiteRating Distribution
Strong Buy
1
7%
Buy / Outperform
8
53%
Hold / Neutral
5
33%
Sell / Underperform
1
7%
Analyst Consensus🟡 Mixed
9 Bullish6 Neutral/Bearish
Price Targets
$56
Average Target
↓ 29.5% Downside
Now
$31
Low
$56
Average
$80
High
Based on 22 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 8th 2025 | JP Morgan | Upgrade | Overweight | $80 |
| September 26th 2025 | Goldman | Upgrade | Neutral | $65 |
| September 3rd 2025 | BMO Capital Markets | Upgrade | Outperform | $70 |
| July 31st 2025 | Morgan Stanley | Upgrade | Overweight | $62 |
| July 1st 2025 | Barclays | Upgrade | Overweight | $57 |
| April 7th 2025 | H.C. Wainwright | Initiation | Buy | $45 |
| March 31st 2025 | Redburn Atlantic | Initiation | Neutral | $39 |
| August 2nd 2024 | BMO Capital Markets | Downgrade | Market Perform | $60← $67 |
| July 24th 2024 | Leerink Partners | Upgrade | Outperform | $62← $53 |
| July 16th 2024 | Jefferies | Resumed | Buy | $75← $29 |
| June 14th 2024 | Bernstein | Upgrade | Market Perform | $44 |
| April 10th 2024 | Wolfe Research | Upgrade | Outperform | $58 |
| January 2nd 2024 | BofA Securities | Upgrade | Buy | $62← $52 |
| October 23rd 2023 | BofA Securities | Upgrade | Neutral | $52← $33 |
| September 29th 2023 | Raymond James | Initiation | Strong Buy | $63 |
Earnings History & Surprises
IONSBeat Rate
88%
Last 16 quarters
Avg Surprise
+58.9%
EPS vs Estimate
Beats / Misses
14/2
Last 12 quarters
Latest EPS
$-0.80
Q4 2025
EPS Surprise History
Q1 24
+92.8%
$-0.06vs$-0.83
Q3 24
+51.1%
$-0.45vs$-0.92
Q4 24
+18.1%
$-0.95vs$-1.16
Q1 25
+39.4%
$-0.66vs$-1.09
Q2 25
+32.4%
$-0.75vs$-1.11
Q3 25
No data
Q4 25
+47.0%
$-0.61vs$-1.15
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $-1.27 | — | — | — |
Q4 2025 | Oct 29, 2025 | — | $-0.80 | — | — |
Q4 2025 | Oct 29, 2025 | $-1.15 | $-0.61 | +47.0% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | — | $0.68 | — | — |
Q2 2025 | Apr 30, 2025 | $-1.11 | $-0.75 | +32.4% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $-1.09 | $-0.66 | +39.4% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.16 | $-0.95 | +18.1% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.92 | $-0.45 | +51.1% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $-0.83 | $-0.06 | +92.8% | ✓ BEAT |
Q1 2024 | Jan 10, 2024 | $-0.83 | $-0.06 | +92.8% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-1.04 | $-1.03 | +1.0% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.90 | $-0.60 | +33.3% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.91 | $-0.87 | +4.4% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-1.06 | $-0.37 | +65.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.74 | $-0.33 | +55.4% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.62 | $-0.74 | -19.4% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.71 | $-0.46 | +35.2% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $0.28 | $1.41 | +403.6% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.53 | $-0.58 | -9.4% | ✗ MISS |
Latest News
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $95
📈 PositiveBenzinga•Dec 17, 2025, 03:02 PM
Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100
📈 PositiveBenzinga•Dec 15, 2025, 08:45 PM
B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $97
📈 PositiveBenzinga•Dec 9, 2025, 05:58 PM
The FDA Has Granted Breakthrough Therapy Designation To Ionis Pharmaceuticals' Zilganersen For Alexander Disease, On Track To Submit New Drug Application In Q1 2026
📈 PositiveBenzinga•Dec 2, 2025, 12:02 PM
Ionis Received FDA Breakthrough Therapy Designation For Olezarsen For Severe Hypertriglyceridemia
📈 PositiveBenzinga•Dec 1, 2025, 12:08 PM
Ionis Pharma And Otsuka Pharma Announce CHMP Of European Medicines Agency Adopts Positive Opinion Of DAWNZERA For Routine Prevention Of Recurrent Attacks Of HAE In Adults
📈 PositiveBenzinga•Nov 14, 2025, 12:04 PM
Ionis Prices $700M 0.00% Convertible Senior Notes Due 2030 To Repurchase And Repay 2026 Notes Using Up To $751.2M Expected Net Proceeds
➖ NeutralBenzinga•Nov 13, 2025, 06:21 AM
CORRECTION: Ionis Pharmaceuticals Announces Proposed $700M Aggregate Amount Convertible Note Offering To Refinance 2026 Convertible Notes
➖ NeutralBenzinga•Nov 11, 2025, 09:13 PM
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $110
📈 PositiveBenzinga•Nov 10, 2025, 12:28 PM
Ionis Pharmaceuticals Study Results Of Olezarsen For Severe Hypertriglyceridemia Show Up To 72% Placebo-adjusted Mean Reduction In Fasting Triglyceride Levels At Six Months, With Reductions Sustained Through 12 Months
📈 PositiveBenzinga•Nov 8, 2025, 03:13 PM
Ionis Pharmaceuticals Releases Long-Term Data For Dawnzera Showing Durable Efficacy And Safety
📈 PositiveBenzinga•Nov 6, 2025, 01:19 PM
Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $77
📈 PositiveBenzinga•Nov 4, 2025, 04:33 PM
TD Cowen Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $99
📈 PositiveBenzinga•Oct 30, 2025, 08:07 PM
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $94
📈 PositiveBenzinga•Oct 30, 2025, 06:19 PM
Barclays Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $95
📈 PositiveBenzinga•Oct 30, 2025, 04:19 PM•Also:
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $100
📈 PositiveBenzinga•Oct 30, 2025, 04:17 PM
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $82
📈 PositiveBenzinga•Oct 30, 2025, 03:19 PM
Raymond James Reiterates Strong Buy on Ionis Pharmaceuticals, Raises Price Target to $89
📈 PositiveBenzinga•Oct 30, 2025, 03:00 PM
Needham Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $90
📈 PositiveBenzinga•Oct 30, 2025, 10:19 AM
Ionis Pharmaceuticals Raises FY2025 Sales Guidance from $825.000M-$850.000M to $875.000M-$900.000M vs $857.588M Est
📈 PositiveBenzinga•Oct 29, 2025, 11:03 AM
Frequently Asked Questions about IONS
What is IONS's current stock price?
Ionis Pharmaceuticals, Inc. (IONS) is currently trading at $79.57 per share. The stock has moved +2.50% today.
What is the analyst price target for IONS?
The average analyst price target for IONS is $86.85, based on 1 analyst.
What sector is Ionis Pharmaceuticals, Inc. in?
Ionis Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IONS's market cap?
Ionis Pharmaceuticals, Inc. has a market capitalization of $12.64 billion, making it a large-cap company.
Does IONS pay dividends?
No, Ionis Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASND
Ascendis Pharma A/S
$199.99
Mkt Cap: $12.1B
BBIO
BridgeBio Pharma, Inc.
$76.30
Mkt Cap: $14.5B
BMRN
BioMarin Pharmaceutical Inc.
$61.15
Mkt Cap: $11.7B
EXEL
Exelixis, Inc.
$44.30
Mkt Cap: $11.9B
GH
Guardant Health, Inc.
$99.74
Mkt Cap: $12.4B
MDGL
Madrigal Pharmaceuticals, Inc.
$591.02
Mkt Cap: $13.1B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
ROIV
Roivant Sciences Ltd.
$22.41
Mkt Cap: $15.6B
RVMD
Revolution Medicines, Inc.
$78.78
Mkt Cap: $15.2B
SMMT
Summit Therapeutics Inc.
$17.82
Mkt Cap: $13.3B
Explore stocks similar to IONS for comparison